While ATRA-induced CD38 upregulation on MM target cells can also induce CD38 levels on CD38 wild-type NK cells, ATRA-induced CD38 upregulation in MM may be counteracted by increased NK cell fratricide and impaired NK cell function, thereby reducing the overall efficacy of daratumumab, whereas deleting the CD38 level on NK cells expanded ex vivo using the CRISPR/Cas9 system could mitigate this situation (Naeimi et al., 2020). Here, CD38 is linked to Miyoshi myopathy.